Xtrackers MSCI China A UCITS ETF (XX25)

Substitute 9% for $19 Billion. ATTR-CM is the heart condition treated with other stabilizers that failed in Phase 3 trial. Has Vascepa been in clinical trials for that condition?

A good 2:13m video in link...

https://x.com/SanCompounding/status/2074871489476878370

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

AZN major clinical trial failure/setback with gene-silencing Wainua drug partnered with IONS.  AZN stock drops ~ $19 Billion. Bloomberg news is source.

Good article! by ?????

Good article! by [https://welove588.com/]?????[https://welove588.com/] insert-text-here

Haier Europe Appoints Stagwell (STGW) as Creative Agency for the Haier Brand, Following Ingenuity+ Pitch ProcessJuly 9, 2026 3:35 AM
ACCESS NewswireLONDON, GB / ACCESS Newswire / July 9, 2026 /

Eliquis is getting hard to find

https://www.medfinder.com/blog/why-is-eliquis-so-hard-to-find-explained-for-2026

As mentioned: Expected news rarely moves stocks.

COB has been telegraphed for a year - promised & pumped & over-promoted.

Nobody cares - expected news is typically fully baked-in.

UNEXPECTED news has a fighting chance.

"Quitting CSE because

I listened for about 5 minutes, lost interest.
Wow...seriously. Where is everybody that listened to the pitch tonight?
Not knocking the call specifically - honestly who cares? Promotion is boring. .

I'm patiently waiting for:

1. An attempt at fixing the s